Koyfin Home > Directory > Health Care > Intellia Thera CS > EBITDA Margin

Intellia Thera CS EBITDA Margin Chart (NTLA)

Intellia Thera CS annual/quarterly EBITDA Margin from 2015 to 2020. An EBITDA margin is a measurement of a company's earnings before interest, taxes, depreciation, and amortization as a percentage of its total revenue.
  • Intellia Thera CS EBITDA Margin for the quarter ending June 06, 2020 was $-193m a -16.57% increase of 32m year over year
  • Intellia Thera CS EBITDA Margin for the last 12 months ending June 06, 2020 was $-227m a -1.36% increase of 3m year over year
  • Intellia Thera CS Annual EBITDA Margin for 2019 was $-234m a -21.43% increase of 50m from 2018
  • Intellia Thera CS Annual EBITDA Margin for 2018 was $-284m a 10.23% decrease of -29m from 2017
  • Intellia Thera CS Annual EBITDA Margin for 2017 was $-255m a 26.06% decrease of -66m from 2016
Other Margins & Efficiency Metrics:
  • Intellia Thera CS Return on Capital % for the quarter ending September 09, 2018 was -22.21 a -16.80% increase of 3.73 year over year
  • Intellia Thera CS Return on Equity % for the quarter ending September 09, 2018 was -33.47 a -20.21% increase of 6.77 year over year
View Chart On Koyfin

Quarterly NTLA EBITDA Margin Data

06/2020$-193m
03/2020$-244m
12/2019$-258m
09/2019$-226m
06/2019$-235m
03/2019$-216m
12/2018$-248m
09/2018$-310m
06/2018$-293m
03/2018$-287m

Annual NTLA EBITDA Margin Data

2019$-234m
2018$-284m
2017$-255m
2016$-188m
2015$-216m